ES2961334T3 - Expresión inducida del factor neurotrófico derivado del cerebro (BDNF) para el tratamiento de enfermedades neuromusculares y/o neurodegenerativas - Google Patents
Expresión inducida del factor neurotrófico derivado del cerebro (BDNF) para el tratamiento de enfermedades neuromusculares y/o neurodegenerativas Download PDFInfo
- Publication number
- ES2961334T3 ES2961334T3 ES16703409T ES16703409T ES2961334T3 ES 2961334 T3 ES2961334 T3 ES 2961334T3 ES 16703409 T ES16703409 T ES 16703409T ES 16703409 T ES16703409 T ES 16703409T ES 2961334 T3 ES2961334 T3 ES 2961334T3
- Authority
- ES
- Spain
- Prior art keywords
- disease
- effective dose
- body weight
- examples
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title claims abstract description 100
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title claims abstract description 100
- 208000018360 neuromuscular disease Diseases 0.000 title claims abstract description 34
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 90
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract description 34
- 230000002232 neuromuscular Effects 0.000 title abstract description 14
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title description 91
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 58
- 201000010099 disease Diseases 0.000 claims abstract description 52
- 206010015037 epilepsy Diseases 0.000 claims abstract description 35
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 18
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 11
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 11
- 230000037396 body weight Effects 0.000 claims description 163
- 208000024891 symptom Diseases 0.000 claims description 91
- 208000018737 Parkinson disease Diseases 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 45
- 206010061818 Disease progression Diseases 0.000 claims description 31
- 230000005750 disease progression Effects 0.000 claims description 31
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 17
- 230000004224 protection Effects 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 149
- 238000000034 method Methods 0.000 abstract description 70
- 241000699670 Mus sp. Species 0.000 abstract description 34
- 230000000626 neurodegenerative effect Effects 0.000 abstract description 26
- 210000004556 brain Anatomy 0.000 abstract description 25
- 208000006289 Rett Syndrome Diseases 0.000 abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 8
- 208000012239 Developmental disease Diseases 0.000 abstract description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract description 6
- 208000006011 Stroke Diseases 0.000 abstract description 6
- 208000035475 disorder Diseases 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 5
- 208000030159 metabolic disease Diseases 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 abstract description 4
- 206010003805 Autism Diseases 0.000 abstract description 4
- 208000020706 Autistic disease Diseases 0.000 abstract description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 abstract description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract description 4
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 4
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 abstract description 4
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 abstract description 4
- 208000024412 Friedreich ataxia Diseases 0.000 abstract description 3
- 208000035180 MODY Diseases 0.000 abstract description 3
- 230000001363 autoimmune Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 208000023328 Basedow disease Diseases 0.000 abstract description 2
- 208000015023 Graves' disease Diseases 0.000 abstract description 2
- 208000006136 Leigh Disease Diseases 0.000 abstract description 2
- 208000017507 Leigh syndrome Diseases 0.000 abstract description 2
- 208000003435 Optic Neuritis Diseases 0.000 abstract description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 2
- 206010025135 lupus erythematosus Diseases 0.000 abstract description 2
- 230000020763 muscle atrophy Effects 0.000 abstract description 2
- 230000008736 traumatic injury Effects 0.000 abstract description 2
- 206010028417 myasthenia gravis Diseases 0.000 abstract 2
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 description 43
- 239000000203 mixture Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 101150083522 MECP2 gene Proteins 0.000 description 7
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 7
- 229950006874 kainic acid Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010034010 Parkinsonism Diseases 0.000 description 6
- 208000028311 absence seizure Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000002045 lasting effect Effects 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 5
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 108091005770 SIRT3 Proteins 0.000 description 4
- 102000000478 Sirtuin 3 Human genes 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 4
- 201000002491 encephalomyelitis Diseases 0.000 description 4
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 206010003628 Atonic seizures Diseases 0.000 description 3
- 206010053398 Clonic convulsion Diseases 0.000 description 3
- 208000002091 Febrile Seizures Diseases 0.000 description 3
- 208000034308 Grand mal convulsion Diseases 0.000 description 3
- 208000025069 Juvenile Huntington disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 208000037158 Partial Epilepsies Diseases 0.000 description 3
- 206010040703 Simple partial seizures Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010043994 Tonic convulsion Diseases 0.000 description 3
- 206010068100 Vascular parkinsonism Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 208000033001 Complex partial seizures Diseases 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 2
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101100520968 Homo sapiens PPP1R1B gene Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100024556 Protein phosphatase 1 regulatory subunit 1B Human genes 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- -1 haloperidol (Haldol) Chemical compound 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 2
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical group [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 1
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000017849 acquired lipodystrophy Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940070343 apokyn Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940097480 cogentin Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940087613 comtan Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 101150069842 dlg4 gene Proteins 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 229940084238 eldepryl Drugs 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 229960004028 eslicarbazepine Drugs 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 230000009599 head growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940062717 keppra Drugs 0.000 description 1
- 229940073092 klonopin Drugs 0.000 description 1
- 229960002623 lacosamide Drugs 0.000 description 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004769 mitochondrial stress Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940020452 neupro Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001474 neuritogenic effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 206010053857 partial lipodystrophy Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960005198 perampanel Drugs 0.000 description 1
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 229940113775 requip Drugs 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 229960003312 retigabine Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 229960003014 rufinamide Drugs 0.000 description 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
- 229940013066 rytary Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940025158 xenazine Drugs 0.000 description 1
- 229940068543 zelapar Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014312 WO2016118741A1 (en) | 2015-01-22 | 2016-01-21 | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2961334T3 true ES2961334T3 (es) | 2024-03-11 |
Family
ID=55310938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16703409T Active ES2961334T3 (es) | 2015-01-22 | 2016-01-21 | Expresión inducida del factor neurotrófico derivado del cerebro (BDNF) para el tratamiento de enfermedades neuromusculares y/o neurodegenerativas |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3247340B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6951976B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102690198B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116617195A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016209255B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017015721A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2974092A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2961334T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1247101A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX392410B (cg-RX-API-DMAC7.html) |
| PT (1) | PT3247340T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016118741A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617195A (zh) | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| EP3641743A2 (en) | 2017-06-23 | 2020-04-29 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20220044150A (ko) * | 2020-09-29 | 2022-04-06 | (주)세포바이오 | Manf를 포함하는 신경정신질환의 예방 또는 치료용 조성물 |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
| JP6706204B2 (ja) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| CN116617195A (zh) * | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
-
2016
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2961334T3 (es) | Expresión inducida del factor neurotrófico derivado del cerebro (BDNF) para el tratamiento de enfermedades neuromusculares y/o neurodegenerativas | |
| Dahmer et al. | Glucosamine | |
| Modi et al. | Medications for migraine prophylaxis | |
| Salardini et al. | Riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial | |
| ES2344920T3 (es) | Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario. | |
| CA2910717C (en) | Biotin for use in treating x-linked adrenoleukodystrophy | |
| Zur | Topical treatment of primary focal hyperhidrosis, part 1 | |
| ES2710937T3 (es) | Métodos para aliviar síntomas de esclerosis múltiple basados en composiciones que contienen apoacuorina | |
| KR102615988B1 (ko) | 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체 | |
| HK40106997A (en) | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | |
| Chou et al. | Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine | |
| Correll et al. | 186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia | |
| Kulisevsky | Safinamide-a unique treatment targeting both dopaminergic and non-dopaminergic systems | |
| CA3076180C (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| EP4670737A1 (en) | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PERIPHERAL NEUROPATHY | |
| ES2326355A1 (es) | Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico. | |
| KUBALANZA | Sublingual Buprenorphine vs. Morphine for Acute Pain | |
| Bozi et al. | The Pharmacological Management of Parkinson’s Disease |